Casi Pharmaceuticals Inc Reports Results For The Quarter Ended In June: Earnings Summary

CASI Pharmaceuticals

20/08/2024 14:31

* CASI Pharmaceuticals Inc  CASI.OQ  reported a quarterly
adjusted
loss of 55 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -77 cents.  The lone analyst forecast for the
quarter was for a loss of 63 cents per share. 
    * Revenue fell 59.5% to $3.98 million from a year ago;
analysts
expected $4.43 million. 
    * CASI Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 52 cents​.
    * The company reported a quarterly loss of $6.97 million.
    * CASI Pharmaceuticals Inc shares had risen by 14.4% this
quarter and lost 12.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for CASI
Pharmaceuticals Inc is $6.00 
This summary was machine generated from LSEG data August 20 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.63          -0.55          Beat
 Mar. 31 2024      -0.05          -0.71          Missed
 Dec. 31 2023      -0.24          -0.45          Missed
 Sep. 30 2023      -0.56          -0.35          Beat